יתרות מזומנים למניה אחת Personalis Genomics (PSNL)

Personalis, Inc. develops precision oncology tests in its laboratories, leveraging demand from pharmaceutical companies. Free cash flow per share illustrates the connection between this production and cloud data storage, where the parameter value equals 1.76. The reliance on IT infrastructure is offset by the humanitarian status of the business, which guarantees stable development regardless of geopolitical sanctions or trade barriers.
פילוחים אנליטיים של חברת Personalis, Inc.

Personalis, Inc. (PSNL) faces risks of liquidity depletion and reliance on equity offerings due to high test promotion costs coupled with slow insurance coverage adoption. The current value of 1.76 reflects the net cash per share, allowing the cash per share metric to assess the business's protection against cash flow gaps and the risk of freezing excess capital.